人肝细胞癌中去唾液酸糖蛋白受体 1 的表达。
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
机构信息
Department of In Vivo Pharmacology - Oncology, Merck Research Laboratories, Merck & Co., Inc., West Point, PA (BS).
出版信息
J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.
Abstract
Human hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Currently, surgical resection is the only effective treatment for HCC if the tumor is resectable. Small molecule, biologics and siRNA anti-cancer drugs have been explored for the treatment of HCC. Selective targeting to tumor tissue rather than normal liver in HCC patients is still a challenge. Galactosamine-mediated targeting delivery of anti-cancer drugs in the liver has been tested because its receptor, asialoglycoprotein receptor 1 (ASGPR1), is expressed in the liver and not in other human tissues. We examined ASGPR1 expression levels by immunohistochemistry in HCC with different grades. Guidance for a targeting delivery strategy for anti-cancer drugs to HCC is suggested in this report.
摘要
人肝癌（HCC）是全球第五大常见癌症。目前，如果肿瘤可切除，手术切除是 HCC 的唯一有效治疗方法。小分子、生物制剂和 siRNA 抗癌药物已被探索用于 HCC 的治疗。在 HCC 患者中，使抗癌药物选择性靶向肿瘤组织而不是正常肝脏仍然是一个挑战。已经测试了半乳糖胺介导的抗癌药物在肝脏中的靶向递送来治疗 HCC，因为其受体，即去唾液酸糖蛋白受体 1（ASGPR1），在肝脏中表达，而不在其他人体组织中表达。我们通过免疫组织化学检查了不同分级 HCC 中的 ASGPR1 表达水平。本报告提出了一种用于 HCC 靶向递药策略的指导意见。
相似文献
1
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.人肝细胞癌中去唾液酸糖蛋白受体 1 的表达。
J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.
2
Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.半乳糖衍生物修饰的纳米颗粒用于高效递送至肝癌的 siRNA。
Biomacromolecules. 2018 Jun 11;19(6):2330-2339. doi: 10.1021/acs.biomac.8b00358. Epub 2018 May 29.
3
Improved method increases sensitivity for circulating hepatocellular carcinoma cells.改良方法提高了对循环肝细胞癌细胞的检测灵敏度。
World J Gastroenterol. 2015 Mar 14;21(10):2918-25. doi: 10.3748/wjg.v21.i10.2918.
4
Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.去唾液酸糖蛋白受体靶向递送阿霉素纳米粒用于肝细胞癌治疗
Drug Deliv. 2017 Nov;24(1):20-29. doi: 10.1080/10717544.2016.1225856.
5
Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin.使用抗唾液酸糖蛋白受体、氨基甲酰磷酸合成酶 1 和细胞角蛋白 pan 的抗体检测肝细胞癌中的循环肿瘤细胞。
PLoS One. 2014 Apr 24;9(4):e96185. doi: 10.1371/journal.pone.0096185. eCollection 2014.
6
Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma.载硼簇糖基化蛋白受体靶向胶束用于肝癌的有效硼中子俘获治疗。
Colloids Surf B Biointerfaces. 2019 Oct 1;182:110397. doi: 10.1016/j.colsurfb.2019.110397. Epub 2019 Jul 24.
7
A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.一种新型多标志物分析方法用于肝细胞癌循环肿瘤细胞的表型分析。
Liver Transpl. 2018 Jul;24(7):946-960. doi: 10.1002/lt.25062.
8
Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.胆管细胞癌和肝细胞癌中与癌症相关的循环大型细胞外囊泡。
J Hepatol. 2017 Aug;67(2):282-292. doi: 10.1016/j.jhep.2017.02.024. Epub 2017 Mar 6.
9
New Small-Molecule Glycoconjugates of Docetaxel and GalNAc for Targeted Delivery to Hepatocellular Carcinoma.新型紫杉醇小分子糖缀合物及其用于肝细胞癌靶向递送的研究
Mol Pharm. 2021 Jan 4;18(1):461-468. doi: 10.1021/acs.molpharmaceut.0c00980. Epub 2020 Dec 2.
10
Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk.乙型肝炎病毒（HBV）受体：肿瘤中缺乏该受体导致HBV感染较少，而肿瘤周围的过表达则导致更高的复发风险。
Oncotarget. 2015 Dec 15;6(40):42952-62. doi: 10.18632/oncotarget.5518.
引用本文的文献
1
Sorafenib-Drug Delivery Strategies in Primary Liver Cancer.索拉非尼在原发性肝癌中的药物递送策略。
J Funct Biomater. 2025 Apr 21;16(4):148. doi: 10.3390/jfb16040148.
2
Unlocking the Potential of Phyto Nanotherapeutics in Hepatocellular Carcinoma Treatment: A Review.解锁植物纳米疗法在肝细胞癌治疗中的潜力：综述
J Hepatocell Carcinoma. 2024 Nov 16;11:2241-2256. doi: 10.2147/JHC.S483619. eCollection 2024.
3
Identification and Analysis of Phenolic Compounds in L. and Its Lipid-Lowering Activity In Vitro.L.中酚类化合物的鉴定与分析及其体外降脂活性
Foods. 2024 Oct 28;13(21):3438. doi: 10.3390/foods13213438.
4
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.利用基于脂质的纳米颗粒进行肝癌治疗的纳米医学策略：探索信号通路和治疗方式。
Adv Pharm Bull. 2024 Oct;14(3):513-523. doi: 10.34172/apb.2024.061. Epub 2024 Jul 31.
5
Detection of γ-OHPdG in Circulating Tumor Cells of Patients With Hepatocellular Carcinoma as a Potential Prognostic Biomarker of Recurrence.检测肝细胞癌患者循环肿瘤细胞中的γ-羟基脱氧鸟苷作为复发的潜在预后生物标志物
Gastro Hep Adv. 2024 Apr 24;3(6):809-820. doi: 10.1016/j.gastha.2024.04.006. eCollection 2024.
6
Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.天然抗氧化剂的纳米制剂治疗肝癌。
Biomolecules. 2024 Aug 19;14(8):1031. doi: 10.3390/biom14081031.
7
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.体内“捕捉-释放”抗 ASGR1 抗体的快速耗竭。
MAbs. 2024 Jan-Dec;16(1):2383013. doi: 10.1080/19420862.2024.2383013. Epub 2024 Jul 25.
8
The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.利用人诱导多能干细胞衍生的肺泡类器官探索 SARS-CoV-2 变体感染和宿主反应。
J Med Virol. 2024 Apr;96(4):e29579. doi: 10.1002/jmv.29579.
9
Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent.细胞摄取和间充质干细胞衍生的细胞外囊泡的体内分布依赖于蛋白质冠。
Nat Nanotechnol. 2024 Jun;19(6):846-855. doi: 10.1038/s41565-023-01585-y. Epub 2024 Feb 16.
10
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes.Asialoglycoprotein receptor 1 促进 SARS-CoV-2 感染人正常肝细胞。
Signal Transduct Target Ther. 2024 Feb 14;9(1):42. doi: 10.1038/s41392-024-01754-y.
本文引用的文献
1
Bioinformatics analysis reveals potential candidate drugs for HCC.生物信息学分析揭示了 HCC 的潜在候选药物。
Pathol Oncol Res. 2013 Apr;19(2):251-8. doi: 10.1007/s12253-012-9576-y. Epub 2013 Jan 23.
2
Cancer statistics, 2013.癌症统计数据，2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
3
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.Polo-like kinase 1 是肝细胞癌的一个新的治疗靶点。
World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.
4
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.半乳糖化的纳米结构脂质载体用于向肝癌递送 5-FU。
J Liposome Res. 2012 Sep;22(3):224-36. doi: 10.3109/08982104.2012.662653. Epub 2012 Mar 5.
5
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.增强子结合锌指蛋白 2 通过表观遗传沉默多个肿瘤抑制 microRNA 促进肝癌转移。
Hepatology. 2012 Aug;56(2):622-31. doi: 10.1002/hep.25679. Epub 2012 Jun 11.
6
Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.从 c-MET 驱动的肝癌小鼠模型中获得的基因特征可预测肝细胞癌患者的生存情况。
PLoS One. 2011;6(9):e24582. doi: 10.1371/journal.pone.0024582. Epub 2011 Sep 16.
7
FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria.FOXM1 表达预测了符合米兰标准的原位肝移植术后肝癌患者的预后。
Cancer Lett. 2011 Jul 28;306(2):214-22. doi: 10.1016/j.canlet.2011.03.009. Epub 2011 Apr 11.
8
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).两种兔单克隆抗体（SP3 和 4B5）和两种原位杂交方法（FISH 和 SISH）检测胃食管腺癌中的 HER2 状态。
Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.
9
RNA interference as therapeutics for hepatocellular carcinoma.RNA 干扰作为肝细胞癌的治疗方法。
Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):106-15. doi: 10.2174/157489211793980097.
10
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma.microRNA-122 作为肝细胞癌中线粒体代谢基因网络的调节剂。
Mol Syst Biol. 2010 Aug 24;6:402. doi: 10.1038/msb.2010.58.
Zotero 插件